CCA
VYNE icon

Catalyst Capital Advisors’s VYNE Therapeutics VYNE Stock Holding History

Catalyst Capital Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3
Closed -$9K – 564
2018
Q1 		$9K Buy
+3
New +$7.3K ﹤0.01% 349

Other funds holding VYNE

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Catalyst Capital Advisors's VYNE Position: Q2 2018 in Review

Catalyst Capital Advisors sold out of VYNE Therapeutics (VYNE) in Q2 2018, closing a stake of 3 shares — an estimated $9K sold.

Catalyst Capital Advisors first reported a position in VYNE in Q1 2018 and held it in 1 quarter. The position peaked at $9K in Q1 2018. 48 funds tracked by Wall St. Rank hold VYNE as of Q2 2018.

  • Catalyst Capital Advisors reported no remaining VYNE Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 3 VYNE Therapeutics shares in Q2 2018, an estimated $9K.
  • Catalyst Capital Advisors first reported a position in VYNE Therapeutics in Q1 2018 and held it in 1 quarter.
  • Catalyst Capital Advisors's VYNE Therapeutics position peaked at $9K in Q1 2018.
  • 48 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2018.

Based on Catalyst Capital Advisors's 13F filing for Q2 2018, filed 7 Aug 2018.